Gepotidacin Crystalline Forms for Stable Antibacterial Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gepotidacin exhibits a strong propensity to form unstable hydrates and solvates, necessitating the development of stable crystalline forms for effective antibacterial applications.
Innovation Solution
The development of novel crystalline forms of gepotidacin, including mesylate dihydrate, anhydrate, and monohydrate, characterized by specific XRPD and Raman spectra, which are thermodynamically stable and suitable for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If gepotidacin is formulated as hydrates or solvates, then it can be prepared through conventional synthesis methods, but the resulting crystalline forms are unstable and unsuitable for pharmaceutical applications
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions (solvent type, temperature, pH) to transform unstable hydrate/solvate forms into stable anhydrous or controlled-hydration forms. Example 1 demonstrates crystallizing gepotidacin mesylate dihydrate from aqueous acetone at controlled temperatures to achieve a stable polymorphic form suitable for pharmaceutical use.
Solution Approach 2:
The patent utilizes phase transitions by controlling the crystallization process to transition gepotidacin from unstable solvate phases to stable crystalline phases. The detailed description shows how controlled cooling and solvent evaporation induce phase transitions that yield thermodynamically stable crystalline forms with defined XRPD patterns.
2Device complexity
If unstable crystalline forms are used, then formulation development is simpler, but the efficacy and reliability of antibacterial treatments are compromised
Solution Approach 1:
The patent applies preliminary action by pre-establishing stable crystalline forms and characterization data before pharmaceutical formulation development. The patent provides comprehensive XRPD, Raman, DSC, and TGA data for each crystalline form, enabling formulation scientists to select appropriate stable forms without needing to perform extensive stability studies.
Solution Approach 2:
The patent identifies and characterizes multiple crystalline forms, allowing selection of the most stable form for each specific application. This enables using simpler, less stable forms only when appropriate, while relying on stable forms for long-term pharmaceutical storage and distribution.
3Stability of the object's composition
If multiple crystalline forms are characterized and developed, then the most stable and suitable form can be selected for pharmaceutical use, but the development time and resources increase
Solution Approach 1:
The patent performs comprehensive characterization of multiple crystalline forms in advance, including XRPD, Raman, DSC, and TGA analyses. This preliminary work establishes a database of stable forms and their properties, eliminating the need for repeated characterization during formulation development and accelerating the overall process.
Solution Approach 2:
The patent systematically varies crystallization parameters (solvent composition, temperature, pH, evaporation rate) to generate and characterize different crystalline forms. By understanding the relationship between parameters and resulting crystal forms, the patent enables rational selection and reproduction of stable forms without exhaustive trial-and-error during development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable crystalline forms of gepotidacin provide a reliable basis for pharmaceutical compositions, enhancing the efficacy and stability of antibacterial treatments against bacterial infections.
Implementation Method 1
The present application relates to novel crystalline forms of gepotidacin
Implementation Method 2
Gepotidacin exhibits a strong propensity to form unstable hydrates and solvates
Data Source
AI summary
Disclosed are novel crystalline forms of gepotidacin and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.